Vitamin B12 levels should be monitored, as GLP-1 agonists can slightly reduce absorptionsomething easily corrected with supplementation
Administered weekly at 2.4 mg subcutaneously, semaglutide has secured regulatory clearance in the United States, Europe, the United Kingdom, and Canada for weight management in adults grappling with overweight (BMI 27 kg m2 alongside at least one obesity-related comorbidity) or obesity (BMI 30 kg m2), backed by findings from the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trial program
J Ethnopharmacol 288:115020
If nausea prevents eating or drinking for more than a few hours, seek urgent care evaluation to rule out gastroenteritis or other conditions unrelated to tirzepatide
A small air bubble in a subcutaneous injection is not dangerous, but precise dosing requires removing excess air
not approved for human or veterinary use.